Secure Your Nasodine® Today TopQuality Nasal Spray
Nasodine Nasal Spray Australia. Our Story Nasodine® Spray Innovates Nasal Cleansing Firebrick's first patent that covers the Nasodine formulation Extends Nasodine's overall patent coverage out to 2041 Patent to be filed internationally in US, EU and other key markets Firebrick Pharma Limited is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray has been accepted in Australia. Every day our noses may be exposed to other people's germs
Firebrick said that the withdrawal was due to "the significant distraction and legal costs associated with proceeding," especially since the company. Independent viral inactivation studies showed that Nasodine rapidly killed all known respiratory viruses - most completely eliminated in less than 60 seconds of contact
Nasodine® Nasal Spray is the product of more than 10 years of pharmaceutical R&D by Firebrick Pharma Ltd, an innovative Australian biopharmaceutical company A study at the Basil Hetzel Institute in Adelaide Australia showed that using a sensitive human nasal tissue model, the nasal formulation was safe for nasal use, even with long term (30 minutes) exposure. Safe and effective, protect your nasal passages with Nasodine Nasal Spray.
Nasodine® Nasal Spray. You could soon be able to use a nasal spray to kill off the common cold "Nasodine is a first-in-class nasal spray medicine that actually targets the viral cause of the common cold, where colds start - in the nose." The primary endpoint of the trial will be the impact of Nasodine treatment (3 sprays per nostril, 4 times daily for 5 days) on overall cold severity in the viral-infected population.
Secure Your Nasodine® Today TopQuality Nasal Spray. A study at the Basil Hetzel Institute in Adelaide Australia showed that using a sensitive human nasal tissue model, the nasal formulation was safe for nasal use, even with long term (30 minutes) exposure. Firebrick Pharmaceuticals announced that it has withdrawn its appeal of a decision by the Therapeutic Goods Administration (TGA), which refused to approve the company's Nasodine povidone-iodine nasal spray as a treatment for the common cold